Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2021
>
Lilly hit by staff accusations, FDA scrutiny at COVID drug factories
Lilly hit by staff accusations, FDA scrutiny at COVID drug factories
Read also
uniQure Staggers as FDA Questions Data for Huntington’s Gene Therapy Candidate
Agency torpedoes company's plans to submit BLA for gene therapy AMT-130 in Q1 2026.
Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn
Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for $48.7bn.
Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges
Femasys (FEMY) on Monday said that the FDA approved continuation of the final phase of its FemBloc pivotal trial, sending shares 25% higher in premarket trading.
Praxis announces
Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
